secwatch.observer — SEC 8-K summary
======================================

Issuer:     Beam Therapeutics Inc. (BEAM)
CIK:        0001745999
Form:       8-K
Filed at:   2022-01-10T23:59:59+00:00
Accession:  0000950170-22-000163
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs
--------------------------------------------------------------------------------

- Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).
- $300M upfront; eligible for up to $1.35B milestones plus royalties.
- Preliminary cash: ~$0.9B actual, $1.2B pro forma including $300M upfront.
- First subject enrollment in BEAM-101 Phase 1/2 trial for sickle cell disease expected H2 2022.
- BEAM-301 (GSDIa) named fourth dev candidate; IND-enabling studies planned in 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/0000950170-22-000163-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1745999/000095017022000163/beam-20220109.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-000163

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer